It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The ketogenic diet (KD) has been shown to be effective in refractory epilepsy after long-term administration. However, its interference with short-term brain metabolism and its involvement in the early process leading to epilepsy remain poorly understood. This study aimed to assess the effect of a short-term ketogenic diet on cerebral glucose metabolic changes, before and after status epilepticus (SE) in rats, by using [18F]-FDG PET. Thirty-nine rats were subjected to a one-week KD (KD-rats, n = 24) or to a standard diet (SD-rats, n = 15) before the induction of a status epilepticus (SE) by lithium-pilocarpine administrations. Brain [18F]-FDG PET scans were performed before and 4 h after this induction. Morphological MRIs were acquired and used to spatially normalize the PET images which were then analyzed voxel-wisely using a statistical parametric-based method. Twenty-six rats were analyzed (KD-rats, n = 15; SD-rats, n = 11). The 7 days of the KD were associated with significant increases in the plasma β-hydroxybutyrate level, but with an unchanged glycemia. The PET images, recorded after the KD and before SE induction, showed an increased metabolism within sites involved in the appetitive behaviors: hypothalamic areas and periaqueductal gray, whereas no area of decreased metabolism was observed. At the 4th hour following the SE induction, large metabolism increases were observed in the KD- and SD-rats in areas known to be involved in the epileptogenesis process late—i.e., the hippocampus, parahippocampic, thalamic and hypothalamic areas, the periaqueductal gray, and the limbic structures (and in the motor cortex for the KD-rats only). However, no statistically significant difference was observed when comparing SD and KD groups at the 4th hour following the SE induction. A one-week ketogenic diet does not prevent the status epilepticus (SE) and associated metabolic brain abnormalities in the lithium-pilocarpine rat model. Further explorations are needed to determine whether a significant prevention could be achieved by more prolonged ketogenic diets and by testing this diet in less severe experimental models, and moreover, to analyze the diet effects on the later and chronic stages leading to epileptogenesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 NANCYCLOTEP-Molecular and Experimental Imaging Platform, Nancy, France; Lorraine University, IADI, INSERM UMR 1254, Nancy, France (GRID:grid.29172.3f) (ISNI:0000 0001 2194 6418)
2 NANCYCLOTEP-Molecular and Experimental Imaging Platform, Nancy, France (GRID:grid.29172.3f); Department of Neuropediatrics, Children’s Hospital CHRU Nancy, Nancy, France (GRID:grid.410527.5) (ISNI:0000 0004 1765 1301)
3 NANCYCLOTEP-Molecular and Experimental Imaging Platform, Nancy, France (GRID:grid.410527.5)
4 CHRU-Nancy, INSERM UMR 1433, CIC, Innovation Technologique, Université de Lorraine, Nancy, France (GRID:grid.410527.5) (ISNI:0000 0004 1765 1301)
5 NANCYCLOTEP-Molecular and Experimental Imaging Platform, Nancy, France (GRID:grid.410527.5); Lorraine University, IADI, INSERM UMR 1254, Nancy, France (GRID:grid.29172.3f) (ISNI:0000 0001 2194 6418); University Hospital, Department of Nuclear Medicine, Nancy, France (GRID:grid.410527.5) (ISNI:0000 0004 1765 1301)
6 Department of Neuropediatrics, Children’s Hospital CHRU Nancy, Nancy, France (GRID:grid.410527.5) (ISNI:0000 0004 1765 1301)
7 NANCYCLOTEP-Molecular and Experimental Imaging Platform, Nancy, France (GRID:grid.410527.5); University Hospital, Department of Nuclear Medicine, Nancy, France (GRID:grid.410527.5) (ISNI:0000 0004 1765 1301)
8 NANCYCLOTEP-Molecular and Experimental Imaging Platform, Nancy, France (GRID:grid.410527.5); Lorraine University, INSERM DCAC1116, Nancy, France (GRID:grid.29172.3f) (ISNI:0000 0001 2194 6418)